<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="HIV began during the epidemics of the early 1980s. HIV" exact="infection" post="was linked with the development of acquired immune deficiency"/>
 <result pre="With no effective antiviral drugs available during that time, a" exact="diagnosis" post="of HIV infection was a death sentence for most"/>
 <result pre="antiviral drugs available during that time, a diagnosis of HIV" exact="infection" post="was a death sentence for most patients [6]. However,"/>
 <result pre="CD4 receptor-expressing cells [5]. Cell-to-cell fusion and transmission of HIV-1" exact="infection" post="were also blocked by GRFT at similar concentrations [5]."/>
 <result pre="might be another plausible mechanism through which GRFT inhibits HIV-1" exact="infection" post="[26]. Since the glycans on HIV-1 gp120 play an"/>
 <result pre="studies have characterized viral resistance profiles caused by chronic GRFT" exact="treatment" post="(Table 5) [25,26,31,39,40]. Since the antiviral activity of GRFT"/>
 <result pre="viability or the levels of T-cell activation markers [43]. GRFT" exact="treatment" post="induced only minimal alterations in the gene expression profile"/>
 <result pre="abundance of two common and beneficial microbial taxa after GRFT" exact="treatment" post="was due to placebo formulations and not to GRFT,"/>
 <result pre="another study [41]. Therefore, an immune response elicited by GRFT" exact="treatment" post="should be controlled in order to avoid potential GRFT"/>
 <result pre="to retain antiviral activity against HIV-1-enveloped pseudoviruses in a cell-based" exact="neutralization assay" post="[41]. In addition, active GRFT, which is capable of"/>
 <result pre="the humanized bone marrow-liver-thymus mice which were protected from vaginal" exact="infection" post="with HIV-1 after being treated with recombinant C. crescentus"/>
 <result pre="[47]. However, GRFT was not orally bioavailable even after chronic" exact="treatment" post="[46]. 9. Large-Scale Production The clinical application of protein"/>
 <result pre="host cells [11]. Preincubation of HCV particles with GRFT prevented" exact="infection" post="of Huh-7 hepatoma cells [13]. Furthermore, GRFT was able"/>
 <result pre="This anti-HCV activity was further demonstrated in vivo when HCV" exact="infection" post="was mitigated in chimeric mice [12]. In this report,"/>
 <result pre="subjects were protected by C. crescentus expressing GRFT after intravaginal" exact="infection" post="with HSV-2 [64]. Levendosky et al. explored the antiviral"/>
 <result pre="and HPV pseudovirus [66]. In vitro experiments showed that the" exact="treatment" post="of JEV with GRFT before inoculation into BHK- 21"/>
 <result pre="JEV with GRFT before inoculation into BHK- 21 cells inhibited" exact="infection" post="in a dose-dependent manner [17]. In vivo experiments showed"/>
 <result pre="experiments showed that GRFT (5 mg/kg) administered intraperitoneally before virus" exact="infection" post="prevented mortality in mice challenged intraperitoneally with a lethal"/>
 <result pre="glycoproteins [16]. In addition, GRFT was able to reduce PEDV" exact="infection" post="in Vero cells [18]. 13. Conclusions Due to its"/>
 <result pre="tenofovir gel, an antiretroviral microbicide, for the prevention of HIV" exact="infection" post="in womenScience20103291168117410.1126/science.119374820643915 8.BeyrerC.BaralS.D.van GriensvenF.GoodreauS.M.ChariyalertsakS.WirtzA.L.BrookmeyerR.Global epidemiology of HIV infection in"/>
 <result pre="of HIV infection in womenScience20103291168117410.1126/science.119374820643915 8.BeyrerC.BaralS.D.van GriensvenF.GoodreauS.M.ChariyalertsakS.WirtzA.L.BrookmeyerR.Global epidemiology of HIV" exact="infection" post="in men who have sex with menLancet201238036737710.1016/S0140-6736(12)60821-622819660 9.LusvarghiS.BewleyC.A.Griffithsin: An"/>
 <result pre="of the family coronaviridaeJ. Virol.2010842511252110.1128/JVI.02322-0920032190 11.MilletJ.K.SeronK.LabittR.N.DanneelsA.PalmerK.E.WhittakerG.R.DubuissonJ.BelouzardS.Middle east respiratory syndrome coronavirus" exact="infection" post="is inhibited by griffithsinAntiviral Res.20161331810.1016/j.antiviral.2016.07.01127424494 12.TakebeY.SaucedoC.J.LundG.UenishiR.HaseS.TsuchiuraT.KnetemanN.RamessarK.TyrrellD.L.ShirakuraM.et al.Antiviral lectins from"/>
 <result pre="and inhibit its infectionVirus Res.2016215505410.1016/j.virusres.2016.01.01626820432 17.IshagH.Z.LiC.HuangL.SunM.X.WangF.NiB.MalikT.ChenP.Y.MaoX.Griffithsin inhibits japanese encephalitis virus" exact="infection" post="in vitro and in vivoArch. Virol.201315834935810.1007/s00705-012-1489-223053519 18.LiL.YuX.ZhangH.ChengH.HouL.ZhengQ.HouJ.In vitro antiviral"/>
 <result pre="griffithsinJ. Gen. Virol.2011922367237310.1099/vir.0.033092-021715597 41.BartonC.KouokamJ.C.LasnikA.B.ForemanO.CambonA.BrockG.MontefioriD.C.VojdaniF.McCormickA.A.Oâ€™KeefeB.R.et al.Activity of and effect of subcutaneous" exact="treatment" post="with the broad-spectrum antiviral lectin griffithsin in two laboratory"/>
 <result pre="potential usesViruses2016833110.3390/v8120331 47.Farr ZuendC.NomelliniJ.F.SmitJ.HorwitzM.S.A caulobacter crescentus microbicide protects from vaginal" exact="infection" post="with HIV-1JR-CSF in humanized bone marrow-liver-thymus miceJ. Virol.20193e00614-1910.1128/JVI.00614-19 48.FuquaJ.L.WangaV.PalmerK.E.Improving"/>
 <result pre="HIV-1 subtype C primary virus isolates TZM-bl and PBMC HIV-1" exact="neutralization assay" post="Loss of glycans at positions 234 and 295 [25]"/>
 <result pre="HIV-1 subtype C primary virus isolates TheTZM-bl and PBMC HIV-1" exact="neutralization assay" post="in PBMC Loss of glycan at positions 230, 234,"/>
 <result pre="mice 108 GRFT-expressing recombinant C. crescentus intravaginally. Protection against HIV-1" exact="infection" post="[47] marinedrugs-17-00567-t008_Table 8Table 8 Large-scale GRFT production methods. N/A"/>
</results>
